Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Integra Lifesciences Holdings (IART) Acquisitions (2016 - 2018)

Integra Lifesciences Holdings' Acquisitions history spans 10 years, with the latest figure at $21.0 million for Q2 2018.

  • For Q2 2018, Acquisitions changed N/A year-over-year to $21.0 million; the TTM value through Sep 2025 reached $21.0 million, down 21.41%, while the annual FY2019 figure was $30.5 million, 214.25% up from the prior year.
  • Acquisitions for Q2 2018 was $21.0 million at Integra Lifesciences Holdings, up from $5.7 million in the prior quarter.
  • Across five years, Acquisitions topped out at $1.0 billion in Q4 2017 and bottomed at -$225000.0 in Q4 2016.
  • The 5-year median for Acquisitions is $53.5 million (2014), against an average of $211.6 million.
  • The largest annual shift saw Acquisitions tumbled 100.07% in 2016 before it soared 451830.67% in 2017.
  • A 5-year view of Acquisitions shows it stood at $85.9 million in 2014, then surged by 282.78% to $328.9 million in 2015, then crashed by 100.07% to -$225000.0 in 2016, then skyrocketed by 451830.67% to $1.0 billion in 2017, then plummeted by 97.93% to $21.0 million in 2018.
  • Per Business Quant, the three most recent readings for IART's Acquisitions are $21.0 million (Q2 2018), $5.7 million (Q1 2018), and $1.0 billion (Q4 2017).